Navigation Links
Study Shows Coronado Biosciences' Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models
Date:1/28/2008

Published Paper Provides Rationale for Continued Development of CNDO103 as

Cancer Treatment

SAN DIEGO, Jan. 28 /PRNewswire/ -- Coronado Biosciences Inc. today announced the publication of data demonstrating that the Bcl-2 inhibitor, Apogossypol, effectively killed a variety of cancer cells in vitro while demonstrating less toxicity than Gossypol in vivo in mice.

Published online in Blood (Jan. 17, DOI 10.1182/blood-2007-09-113647) by the Burnham Institute's president and CEO, John Reed, M.D., Ph.D., and collaborators, the paper summarized study findings demonstrating that mice treated with Apogossypol experienced less hepatotoxicity and gastrointestinal toxicity than those treated with Gossypol. The results support Coronado Biosciences' continued development of its lead candidate, CNDO103, as a cancer treatment.

"Apogossypol was rationally designed to eliminate the toxicities seen with Gossypol," said Reed. "This study provides strong evidence that Apogossypol is better tolerated by the animals without a compromise in potency in vitro. We hope these preclinical results translate to humans. If they do, Apogossypol can play a role in the treatment of many types of cancers."

Maurizio Pellecchia, Ph.D., a professor at the Burnham Institute of Medical Research, developed Apogossypol using NMR guided rational drug design. "Based on our molecular modeling, we predicted that Apogossypol would be equally potent in killing cancer cells but safer than the parent compound Gossypol," said Pellecchia. "It is gratifying that the exhaustive set of experiments reported in the paper support our predictions."

RJ Tesi, M.D., president and CEO of Coronado Biosciences, added: "The data reinforce our decision to push rapidly to the clinic with Apogossypol. We plan to perform IND-enabling preclinical studies for Apogossypol, CNDO103, in the first half of the year. If the toxicity profile in animals approximates what was
'/>"/>

SOURCE Coronado Biosciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...RONTO,Nov.24/PRNewswire-FirstCall/-HamiltonThorneL...providerofadvancedlasersystemsandinstrumentsforthe...ortedoperationalandfinancialresultsforthethirdquar...evenuewas$1.46millioncomparedwith$1.43millioninQ32....1percentinQ3,2008,-Netlossreducedto$148,000compar...
(Date:11/24/2009)...4/PRNewswire-FirstCall/--GenomicHealth,Inc.(Nasdaq...,sExecutiveChairman,willpresentatthe21stAnnualPipe...,December1,2009at10:00a.m.ET. ,, Toaccesstheliv...isittheInvestorRelationssectionofGenomicHealth,swe...onnecttothewebsiteatleast15minutespriortothebeginn...
(Date:11/24/2009)...al Abstracts Service (CAS), the global expert on c...ffice is now the world,s leading producer of paten...ed Japan,s patent office, the World Intellectual P... Patent and Trademark Office (USPTO) for more than...006, and exceeded Japan for the first time on a mo...
(Date:11/23/2009)... of it as origami very high-tech origami. , Rese...ed a technique for fabricating three-dimensional, ...lms by coupling photolithography and a self-foldin... films, only a few microns thick, offer mechanical...ces of the same material. , "This is a completely...
Breaking Biology Technology:Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Genomic Health to Present at Piper Jaffray Health Care Conference 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 3Water droplets direct self-assembly process in thin-film materials 2
...als, Inc. (Nasdaq: ISIS ) announced today that it...(Ibis), has been awarded four new,government contr...tection,and identification of microbial threat age...ntracts are from the Department of Homeland Securi...d total up to approximately,$3.3 million and a fou...
...SE: EHP) announced today that it has completed the... for potential biodefense drugs, and are,about to ...over the coming,year. The National Institutes of ...logical and Nuclear Threats (MCART) programme lead...ion sickness following a nuclear terrorist,attack....
...:,BIOD) today announced that it will amend its Qua...d ended June 30, 2007 to correct the manner in whi...nsation expense arising from,stock options granted...any,s initial public offering. The amendment will ...olely non-cash in nature. On May 10, 2007, the Co...
Other Biology Technology:Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development 2Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development 3Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development 4EpiStem Successfully Complete First Year of Mucositis Tests for NIH Biodefence Programme 2EpiStem Successfully Complete First Year of Mucositis Tests for NIH Biodefence Programme 3Biodel to Amend June 30, 2007 10-Q to Correct Non-Cash Share-Based Compensation Expense 2Biodel to Amend June 30, 2007 10-Q to Correct Non-Cash Share-Based Compensation Expense 3
(Date:11/23/2009)...ence that the "synergistic" effect of early-life e...and indoor endotoxin causes more harm to developin... Environmental health scientists at the Universit...n that children exposed to both high levels of tra... early life are six times more likely to experienc...
(Date:11/23/2009)...plied mathematicians dissected the morphology of t...istic long leaf with a saddle-like arc midsection ...mple cause of the lily,s fan-like shapeelastic rel... growthwas revealed by using an equally simple tec...a postdoctoral student at Harvard,s School of Engi...
(Date:11/23/2009)...Society says that western lowland gorillas living ...he "mother lode" of more than 125,000 gorillas dis...ned by growing humans activity in the region. , ...ts adjacent to the southwest border of Lac Tl Comm...high densities of the great apes still exist in th...
Breaking Biology News(10 mins):Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2The cause behind the characteristic shape of a long leaf revealed 2A year after discovery, Congo's 'mother lode' of gorillas remains vulnerable 2Watchful waiting is a viable option for prostate cancer patients with low risk tumors 55761 1Watchful waiting is a viable option for prostate cancer patients with low risk tumors 55761 2Watchful waiting is a viable option for prostate cancer patients with low risk tumors 55761 3Abbott to Present at Morgan Stanley Global Healthcare Unplugged Conference 55759 1Family Circle Magazine Features AmLactin 28R 29 in Article on Managing Dry Skin Associated With Keratosis Pilaris 55757 1Family Circle Magazine Features AmLactin 28R 29 in Article on Managing Dry Skin Associated With Keratosis Pilaris 55757 2
...or bioengineered crops, sequencing the genome coul.... Once the sequence is complete, the baton is pass...ions. A draft sequence of the soybean genome is no...able soon. Taking the next step in a new study, Un... researchers have demonstrated the applicability o...
...entory" of sea and land animals around a group of ... biodiversity and has more species than the Galapa...monitor how they will respond to future environmen... of Biogeography , the team from British Antarctic...ey combed the land, sea and shores of the South Or...
...(Sweden) Permission has been granted to start the...or a remedy for ALS. ALS is an incurable, paralyzi...ns in every 100,000. The disease commonly affects ...lives − without warning. Researchers from VI...ibilities for the use of VEGF in the treatment of ...
Other Biology News:Tool helps identify gene function in soybeans 2First trial in patients with a potential treatment of the incurable ALS muscle disease 2First trial in patients with a potential treatment of the incurable ALS muscle disease 3
...DA-GT12 Genetic Analyzer is a revolutionary multi...ultiple applications in one instrument platform. I...data analysis in one step, thus significantly impr... of medium to high-throughput laboratories . Bene...
...otofor purification system, 100-120 V, is used for...se isoelectric focusing (IEF). The system includes...ng chambers, chassis, harvesting apparatus, coolin...lytes (pH 3-10), 60 ml syringe, colored protein sa...
...mmEdge Pen, a hydrophobic barrier pen for immunohi...ed for use with frozen or paraffin-embedded tissue... provides a heat-stable, water-repellent barrier t...e sections, prevents mixing of reagents when diffe...
NBT/BCIP Chromogen System (SIGNET) from Covance Research Products, Inc
Biology Products: